Renaissance Capital logo

Prosensa Priced, Nasdaq: RNA.X

Late-stage biotech developing treatments for Duchenne muscular dystrophy.

Industry: Health Care

First Day Return: +48.1%

Late-stage biotech developing treatments for Duchenne muscular dystrophy.

Prosensa (RNA.X) Performance

Created with Highcharts 10.3.2Chart context menuRNA.X vs. IPO Index (IPOUSA)2014201520162017201820192020202120222023202420250%+ 200%+ 400%-200%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index